Condition: Opioid Use Disorder · Opioid Abuse and Addiction · Narcotic-Related Disorders · Sponsor: Milton S. Hershey Medical Center
The goal of this clinical trial is to learn if semaglutide can reduce illicit opioid use in adults in outpatient treatment for opioid use disorder, and who are receiving either buprenorphine or methadone maintenance treatment. The main question it aims to answer is: • Does semaglutide increase the likelihood that participants will refrain from using illicit and nonprescribed opioids? The investigators will compare semaglutide to a placebo (a needle prick that contains no drug) to see if semaglutide works to reduce use of illicit and nonprescribed opioids. The participants will: * Take semaglutide or a placebo every week for 12 weeks * Visit the clinic every week for urine drug screening and pregnancy testing, vital signs, and to complete mental health and drug use questionnaires * Complete smartphone surveys sent at set times during the study
This description comes directly from the study's public registry record.
Jennifer Nyland, PhD · 717-531-6172 · jnyland@pennstatehealth.psu.edu
Kirsten Shuler, MSc · 717-531-4104 · kshuler@pennstatehealth.psu.edu
Always discuss trial participation with your own doctor first.
| University of Maryland Baltimore | Baltimore, Maryland, United States | Completed |
| Stanley Street Treatment and Resources | Fall River, Massachusetts, United States | Not Yet Recruiting |
| NYU Langone Health | New York, New York, United States | Recruiting |
| Pennsylvania Psychiatric Institute | Harrisburg, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06548490